NCI CIP-Net (@nci-cipnet.org)

#CIPNetPublication in Nature Cancer by Dr. Madhav Dhodapkar: The MyCheckpoint randomized trial reports durable clinical responses in multiple myeloma following TIGIT or LAG3 immune checkpoint blockade, with distinct pathway-specific immune correlates for each arm. pubmed.ncbi.nlm.nih.gov/39187595/

loading . . .

Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial - PubMed Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was we … https://pubmed.ncbi.nlm.nih.gov/39187595/